All News

Found 1,994 articles

• Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

  5/10/2023

  Syros Pharmaceuticals today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.

• The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy

  5/9/2023

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801)and Eli Lilly and Company ("Lilly", NYSE: LLY), jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection).

• MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

  5/9/2023

  MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023.

• Laronde Announces New Leadership - May 08, 2023

  5/8/2023

  Laronde, the company pioneering Endless RNA™ – a novel, engineered form of RNA that can be programmed to express proteins inside the body for breakthrough treatments – announced that Pablo J. Cagnoni, M.D., will step down from his role as Chief Executive Officer effective May 26, 2023, to become President and Head of Research & Development of Incyte.

• Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

  5/8/2023

  Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.

• Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine

  5/8/2023

  Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.

• Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

  5/8/2023

  Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.

• Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

  5/8/2023

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended March 31, 2023 and provided a business update.

• Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update

  5/4/2023

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the first quarter and provided a business update.

• MorphoSys AG Reports First Quarter 2023 Financial Results

  5/3/2023

  MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.

• Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

  5/2/2023

  Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

• Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

  5/1/2023

  Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce disease severity in adult patients with atopic dermatitis (AD), the most common type of eczema.

• Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

  4/20/2023

  Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

• Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

  4/20/2023

  Innovent Biologics, Inc., announced that the overall survival results of the Phase 2 study of pemigatinib in Chinese patients with advanced cholangiocarcinoma were presented at the American Association for Cancer Research Annual Meeting 2023.

• Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

  4/18/2023

  Innovent Biologics, Inc. announced the final analysis results of ORIENT-16, the Phase 3 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction cancer at the American Association for Cancer Research Annual Meeting 2023.

• Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

  4/18/2023

  Innovent Biologics, Inc. announced the updated results of IBI351 from a phase 1 clinical trial in an oral presentation at the 2023 American Association for Cancer Research Annual Meeting.

• Incyte to Present at Upcoming Investor Conferences - April 18, 2023

  4/18/2023

  Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May.

• Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

  4/17/2023

  Innovent Biologics, Inc. announced that the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in a poster presentation at the American Association for Cancer Research Annual Meeting 2023.

• Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting

  4/17/2023

  Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023.

• MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

  4/16/2023

  MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi® plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma.